Zydus Lifesciences's shares increase after the USFDA provides six comments

 Zydus Lifesciences's shares increase after the USFDA provides six comments

Zydus Lifesciences's shares increase after the USFDA provides six comments

According to the firm, no duplicates from an earlier examination or findings pertaining to data integrity were found.

Early on December 26, Zydus Lifesciences' stock price shot up after the US Food and Drug Administration (USFDA) sent six comments to the firm without reversing any of them.

Zydus Lifesciences was up Rs 2.05, or 0.30 percent, on the BSE at 9:29 a.m., trading at Rs 682.00.

The Changodar, Ahmedabad, API facility was inspected by the USFDA. The business said that six observations were made at the conclusion of this PAI-cum-GMP USFDA inspection, which took place between December 14 and 22.

It said that no duplicates from an earlier examination or observations pertaining to data integrity were found.

The USFDA has approved the four medication master files on the website, and the company will collaborate closely with the agency to resolve the comments.

The US FDA granted the business final permission last week to produce and distribute Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg, which are intended to treat primary generalized tonics and partial-onset seizures. The same is true with medications. seizures clonic.

The USFDA gave the business final clearance earlier this month to produce and sell Methylene Blue Injection, which comes in doses of 10 mg/dl and 50 mg/dl.

An oxidation-reduction drug called methylene blue injection is used to treat acquired methemoglobinemia in adults and children.